Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 ADME and absolute bioavailability study of PF-06651600 in healthy male volunteers
NL-OMON48152Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ritlecitinib tosilate in autoimmune disease, Inflammatory Disorders, autoimmune colitis and 3 more, sponsored by Pfizer. Primary endpoint: Mass balance. Started Apr 2019; status: active, not recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
autoimmune diseaseInflammatory Disordersautoimmune colitisalopecia areatarheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON48152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48152.